Resistance to antiretroviral drugs in treated and drug-naive patients in the democratic Republic of Congo

Journal of Acquired Immune Deficiency Syndromes

Volumn 57, Issue SUPPL. 1, 2011, Pages

  Muwonga, Jérémie ^a,b   Edidi, Samuel ^a   Butel, Christelle ^c   Vidal, Nicole ^c   Monleau, Marjorie ^c   Okenge, Augustin ^d   Mandjo, Jean Lambert ^d   Mukumbi, Henry ^e   Muyembe, Jean Jacques ^b   Mbayo, Ferdinand ^b   Nzongola, Donatien Kayembe ^b   Delaporte, Eric ^c   Boillot, François ^f,g   Peeters, Martine ^c  

^a General Hospital of Kinshasa   (Congo)

^b UNIVERSITY OF KINSHASA   (Congo)

^c INSTITUT DE RECHERCHE POUR LE DÉVELOPPEMENT   (France)

^d AIDS National Control Program (PNLS)   (Congo)

^e AMO Congo ^*  (Congo)

^f Alter Santé Internationale and Développement   (France)

^g INTERNATIONAL UNION AGAINST TUBERCULOSIS AND LUNG DISEASE   (France)

Author keywords

Africa; Democratic Republic of Congo; drug resistance; HIV

Indexed keywords

ABACAVIR; ANTIRETROVIRUS AGENT; EFAVIRENZ; ETRAVIRINE; LAMIVUDINE; NEVIRAPINE; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; TENOFOVIR; ZIDOVUDINE;

ADULT; ANTIVIRAL RESISTANCE; ARTICLE; CONGO; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; VIRUS LOAD;

ADULT; ANTI-HIV AGENTS; CROSS-SECTIONAL STUDIES; DEMOCRATIC REPUBLIC OF THE CONGO; DRUG RESISTANCE, VIRAL; FEMALE; HIV INFECTIONS; HUMANS; MALE; MIDDLE AGED; MUTATION; VIRAL LOAD;

EID: 79959705388     PISSN: 15254135     EISSN: 10779450     Source Type: Journal    
DOI: 10.1097/QAI.0b013e31821f596c     Document Type: Article

References (31)

1. Cohen J. The rise and fall of Project SIDA. Science. 1997;278:1565-1568.
2. Braeckman C. Les nouveaux predateurs. Politique des puissances en Afrique centrale. Bruxelles, Belgium: Aden; 2003:1-394.
3. USAID's HIV/AIDS Web site for the DRC. Available at: http:// www.usaid.gov/our-work/global-health/aids/Countries/africa/congo.html. Accessed February 1, 2011.
4. UNAIDS. Epidemiological Fact Sheet on HIVand AIDS, 2008. Available at: http://www.unaids.org/en/dataanalysis/epidemiology/epidemiological factsheets. Accessed February 1, 2011.
5. Gilks CF, Crowley S, Ekpini R, et al. The WHO public-health approach to antiretroviral treatment against HIV in resource-limited settings. Lancet. 2006;368:505-510. (Pubitemid 44142772)
6. Kantor R, ShaferRW, Follansbee S, et al. Evolution of resistance to drugs in HIV- 1-infected patients failing antiretroviral therapy. AIDS. 2004;18:1503-1511. (Pubitemid 39037474)
7. Gupta RK, Pillay D. HIV resistance and the developing world [review]. Int J Antimicrob Agents. 2007;29:510-517. (Pubitemid 46562507)
8. Bennett DE, Bertagnolio S, Sutherland D, et al. The World Health Organization's global strategy for prevention and assessment of HIV drug resistance. Antivir Ther. 2008;13(suppl 2):1-13. (Pubitemid 352019085)
9. Rouet F, Foulongne V, Viljoen J, et al. Comparison of the generic HIV viral load assay with the Amplicor HIV-1monitor v1.5 and Nuclisens HIV-1 EasyQ v1.2 techniques for plasma HIV-1 RNA quantitation of non-B subtypes: the Kesho Bora preparatory study. J Virol Methods. 2010;163:253-257.
10. Vergne L, Diagbouga S, Kouanfack C, et al. HIV-1 drug-resistance mutations among newly diagnosed patients before scaling-up programmes in Burkina Faso and Cameroon. Antivir Ther. 2006;11:575-579. (Pubitemid 44277422)
11. Bennett DE, Camacho RJ, Otelea D, et al. Drug resistance mutations for surveillance of transmitted HIV-1 drug resistance: 2009 update. Plos One. 2009;4:e4724.
12. Vidal N, Mulanga C, Bazepeo SE, et al. HIV type 1 pol gene diversity and antiretroviral drug resistance mutations in the Democratic Republic of Congo (DRC). AIDS Res Hum Retroviruses. 2006;22:202-206. (Pubitemid 43277157)
13. Andries K, Azijn H, Thielemans T, et al. TMC125, a novel next-generation nonnucleoside reverse transcriptase inhibitor active against nonnucleoside reverse transcriptase inhibitor-resistant human immunodeficiency virus type .1. Antimicrob Agents Chemother. 2004;48:4680-4686. (Pubitemid 39577672)
14. Coutsinos D, Invernizzi CF, Xu H, et al. Factors affecting template usage in the development of K65R resistance in subtype C variants of HIV type-1. Antivir Chem Chemother. 2010;20:117-131.
15. Martinez-Cajas JL, Pai NP, Klein MB, et al. Differences in resistance mutations among HIV-1 non-subtype B infections: a systematic review of evidence (1996-2008). J Int AIDS Soc. 2009;12:11.
16. Tassie JM, Baijal P, Vitoria MA, et al. Trends in retention on antiretroviral therapy in national programs in low-income and middle-income countries. J Acquir Immune Defic Syndr. 2010;54:437-441.
17. Vidal N, Peeters M, Mulanga-Kabeya C, et al. Unprecedented degree of human immunodeficiency virus type 1 (HIV-1) group M genetic diversity in the Democratic Republic of Congo suggests that the HIV-1 pandemic originated in Central Africa. J Virol. 2000;74:10498-10507.
18. Yang C, Li M, Mokili JL, et al. Genetic diversification and recombination of HIV type 1 group M in Kinshasa, Democratic Republic of Congo. AIDS Res Hum Retroviruses. 2005;21:661-666. (Pubitemid 41113655)
19. Djoko CF, Rimoin AW, Vidal N, et al. High HIV type 1 group M pol diversity and low rate of antiretroviral resistance mutations among the uniformed services in Kinshasa, DRC. AIDS Res Hum Retroviruses. 2011; 27:323-329.
20. Muula AS, Ngulube TJ, Siziya S, et al. Gender distribution of adult patients on highly active antiretroviral therapy (HAART) in Southern Africa: a systematic review. BMC Public Health. 2007;7:63.
21. Ochieng-Ooko V, Ochieng D, Sidle JE, et al. Influence of gender on loss to follow-up in a large HIV treatment programme in western Kenya. Bull World Health Organ. 2010;88:681-688.
22. Barth RE, van der Loeff MF, Schuurman R, et al. Virological follow-up of adult patients in antiretroviral treatment programmes in sub-Saharan Africa: a systematic review. Lancet Infect Dis. 2010;10:155-166.
23. Kouanfack C, Montavon C, Laurent C, et al. Low levels of antiretroviralresistant HIV infection in a routine clinic in Cameroon that uses theWorld Health Organization (WHO) public health approach to monitor antiretroviral treatment and adequacy with the WHO recommendation for second-line treatment. Clin Infect Dis. 2009;48:1318-1322.
24. Hosseinipour MC, van Oosterhout JJ, Weigel R, et al. The public health approach to identify antiretroviral therapy failure: high-level nucleoside reverse transcriptase inhibitor resistance among Malawians failing firstline antiretroviral therapy. AIDS. 2009;23:1127-1134.
25. Braitstein P, Boulle A, Nash D, et al. Antiretroviral Therapy in Lower Income Countries (ART-LINC) study group. Gender and the use of antiretroviral treatment in resource-constrained settings: findings from a multicenter collaboration. J Womens Health. 2008;17:47-55. (Pubitemid 351197536)
26. Ferradini L, Jeannin A, Pinoges L, et al. Scaling up of highly active antiretroviral therapy in a rural district of Malawi: an effectiveness assessment. Lancet. 2006;367:1335-1342.
27. Chen SC, Yu JK, Harries AD, et al. Increased mortality of male adults with AIDS related to poor compliance to antiretroviral therapy in Malawi. Trop Med Int Health. 2008;13:513-519. (Pubitemid 351533602)
28. Blanco JL, Rhee SY, Varghese V, et al. Variation in drug resistance mutation prevalence unrelated to ARV-selection pressure may explain varying estimates of genotypic resistance in studies from sub-Saharan Africa and South East Asia. In: 18th Conference on Retroviruses and Opportunistic Infections; February 27-March 2, 2011; Boston, MA. Abstract 615.
29. Descamps D, Chaix ML, Montes B, et al. Increasing prevalence of transmitted drug resistance mutations and non-B subtype circulation in antiretroviral-naive chronically HIV-infected patients from 2001 to 2006/ 2007 in France. J Antimicrob Chemother. 2010;65:2620-2627.
30. Wensing AM, van de Vijver DA, Angarano G, et al. Prevalence of drugresistant HIV-1 variants in untreated individuals in Europe: implications for clinical management. J Infect Dis. 2005;192:958-966. (Pubitemid 41266791)
31. WHO. Antiretroviral therapy for HIV infection in adults and adolescents. Recommendations for a public health approach (2010 version). Available at: http://www.who.int/hiv/pub/arv/adult2010/en/index.html. Accessed February 1, 2011.